# Development of a clinical implementation plan (CarePath) for a novel urine exosome gene expression assay as part of a two-cohort, adaptive decision impact utility trial

McKiernan J<sup>1</sup>, Donovan MJ<sup>2</sup>, Margolis A<sup>3</sup>, Partin A<sup>4</sup>, Carter B<sup>4</sup>, Brown A<sup>5</sup>, Torkler P<sup>6</sup>, Noerholm M<sup>6</sup>, Bentis C<sup>7</sup>, Skog J<sup>7</sup>, Shore N<sup>8</sup>, Andriole G<sup>9</sup>, Etzioni R<sup>10</sup>, Thompson I<sup>11</sup>, Carroll P<sup>12</sup>

(1) Columbia University Medical Center, NYC, NY; (2) Icahn School of Medicine at Mt. Sinai, NYC, NY; (3) Urology Center of Englewood, Englewood, NJ; (4) Johns Hopkins Hospital, Baltimore, MD; (5) Delaware Valley Urology, Vorhees, NJ; (6) Exosome Diagnostics GmbH, Martinsried, Germany; (7) Exosome Diagnostics, Waltham, MA; (8) Atlantic Urology Clinics, Myrtle Beach, SC; (9) Washington University, St. Louis, MO; (10) Fred Hutchinson Cancer Research Center, Seattle WA; (11) UT Health Science Center, San Antonio, TX;

# MP46-05

## Introduction:

The ability to discriminate indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important health issue. In Phase 1 of a prospective decision impact trial we conducted a 503 patient second independent validation study (Cohort 1) and assessed performance of the ExoDx Prostate(IntelliScore) (EPI) urine exosome test (Figure 1) for discriminating Grade group (GG)  $\geq$  2 from GG1 PCa and benign disease on initial biopsy. We then convened an expert panel to review these results and developed a clinical implementation EPI guidance document (i.e. CarePath) for a second patient cohort (Cohort 2) (Figure 2) where EPI results are provided during the initial biopsy decision process [1].

(12) University of California at San Francisco, CA





Figure 1: Schematic overview of the ExoDx™ Prostate(IntelliScore) (EPI) assay.

## **Methods:**

A panel of clinicians and risk modeling experts compared the area under the receiver operating characteristic curve (AUC), negative predictive value (NPV), sensitivity, and specificity of cohort 1 EPI outcomes (N=503) with previous validation results (N=519) for both the validated and alternative EPI cutpoints of 15.6 and 20. The group compared EPI cut-point performances in a derived pooled cohort (N=1022: Cohort 1 N=503 + previous validation N=519).



**Figure 2**: Schematic overview of the adaptive, prospective clincial trial design. After completion of phase 1, a panel of clinicians and risk modeling experts convened at a Consensus Conference to review the performance of the EPI test and compare with previous validation study results using both the validated and alternative cut-points of 15.6 and 20, respectively.

# Results:

Expert consensus confirmed comparable performances for discriminating GG2 PCa or greater from benign and GG1 PCa disease in Cohort 1 (EPI AUC 0.70) (**Figure 3** (a)), with the original validation cohort (EPI AUC 0.71) and in the pooled cohort (EPI AUC 0.70) (**Figure 3** (b)). Using the previously validated cut-point of 15.6 (or alternative 20) would avoid 26% (or 40%) of unnecessary prostate biopsies and 20% (or 31%) of total biopsies, with an NPV of 89% for both cut-points, and missing only 7% (or 11%) of  $\geq$ GG3, respectively. Results were also comparable for the pooled cohort.

#### Phase 1 **Pooled Cohort** Cohort 1 N = 503N = 1022AUC: 0.70 AUC: 0.70 EPI SOCm+ EPI AUC: 0.71 SOCm+ EPI AUC: 0.71 0.2 -SOCm AUC: 0.62 SOCm AUC: 0.62 AUC: 0.62 AUC: 0.63 AUC: 0.59 AUC: 0.57 PSA AUC: 0.56 AUC: 0.58 1 - Specificity 1 - Specificity **Table 1: Demographics & Performance** B **Pooled Cohort** Cohort 1 **Cohort Size** 1022 503 Age (Median) 63 years 64 years **PSA** (Median) 5.3 ng/mL 5.4 ng/mL **African American** 15.5% 14.1% Familyhistory - Yes 18.5% 14.3% Validated (15.6) Alternative (20) **EPI Cutpoint** Alternative (20) Validated (15.6) 31.4% 29.9% 29.9% 31.4% **Prevalence HGPCa Biopsies Avoided** 20.1% 30.8% 23.4% 33.8% 88.2% 93.0% 89.2% 92.5% Sensitivity 26.1% 30.2% 43.2% 40.0% **Specificity** 89.6% 89.1% 89.0% 90.4% **NPV**

**Figure 3**: After completion of Phase 1 the results were reviewed in combination with previously developed validation data, separately and in a pooled analysis of all N=1022 subjects.

### References:

[1] McKiernan J, Donovan MJ, Margolis A, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Etzioni R, Thompson I, Carroll P (2018) A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with PSA 2-10 ng/mL at initial biopsy. *European Urology*, Manuscript submitted

#### Consensus CarePath Meeting **Attendees:** James M. McKiernan Columbia University Medical Center Michael J. Donovan Icahn School of Medicine at Mt. Sinai Eric J. Margolis **Urology Center of Englewood** Alan W. Partin Johns Hopkins Hospital H Ballentine Carter **Objectves:** Johns Hopkins Hospital Gordon A. Brown Comprehensive review of the Phase 1 outcome Delaware Valley Urology Develop clinical implementation CarePath for EPI test Neal Shore Atlantic Urology Clinics Assess patient eligibility and cohort demographics Gerald L. Andriole Determine if primary endpoint was achieved Washingtion University, St. Louis Ruth Etzioni Confirm intended use population Fred Hutchinson Cancer Research Center Ian Thompson Recommend cut-point for EPI test **UT Health Science Center** Finalize CarePath document for Phase 2 Peter Carroll

# CarePath

# EXODX™ Prostate(IntelliScore)

#### The Consensus CarePath Meeting Attendees agreed:

- The EPI test is to be utilized at the original validated cut-point of 15.6
- Patients with an EPI score <15.6 are considered low risk for having HGPCa (≥GG2)</li>
- Patients with an EPI score ≥15.6 are considered high risk for having HGPCa (≥GG2)
- EPI is designed to be used in conjunction with standard of care prognostic information

# Phase 2

# Phase 2 / Decision Impact Cohort:

- Provide EPI CarePath Document to Principal Investigators participating in Phase 2
- Assess impact of EPI results on biopsy decision process
- Determine health economics of EPI in biopsy decision process
- Assess physician and patient satisfaction

University of California